Konference: 2014 39th Congress ESMO - účast ČR
Kategorie: Gastrointestinální nádory
Téma: Postery
Číslo abstraktu: 1134PD
Autoři: Prof. M.D. Philippe B. Ruszniewski; Prof. M.D. Martyn E. Caplin, FRCP; M.D. Juan W. Valle; Catherine Lombard-Bohas; Graeme John Poston; M.D. Petros Perros, BSc, MBBS, FRCP; Doc. MUDr. Luboš Holubec (jr.), Ph.D., MBA; Prof. M.D. Gianfranco Delle Fave; Denis Michel Smith; Patricia Niccoli; Pascal Maisonobe; Philippe Atlan
Aim
CS associated with NETs can have a negative impact on patients' QoL. Here, QoL data are evaluated from the SymNET study.
Methods
SymNET was a large observational study of NET patients with a history of CS-related diarrhoea treated with LAN for >3 mo (NCT01234168). Patient-reported outcomes were assessed at a routine clinic visit. Primary endpoint was patient satisfaction with diarrhoea control (PSD). Symptoms were evaluated using medical records. QoL was assessed using the EORTC QLQ-C30 and QLQ-GI.NET21 questionnaires, which assess functional dimensions (QLQ-C30; higher scores = better QoL) and symptoms (QLQ-C30 and QLQ-GI.NET21; lower scores = better QoL). Overall QoL was evaluated according to satisfaction with CS symptom control.
Results
Among 273 patients enrolled, 76% [95% CI: 70, 81%] were ‘completely’ or ‘rather’ satisfied with diarrhoea control. There was a clinically significant reduction in stool number and statistically significant improvements in urgency, leakage, and associated pain since LAN initiation. Scores for the QLQ-C30 global health status were high (mean [SD] 65.5 [22.1], median [range] 66.7 [0–100]), while scores for the QLQ-GI.NET21 endocrine and gastrointestinal subscales were low (endocrine, mean [SD] 19.4 [21.3], median [range] 11.1 [0–100]; gastrointestinal, mean [SD] 22.9 [17.8], median [range] 20.0 [0–87]). Patients who expressed a high PSD scored well on their overall rating of QoL (Table); in total, 70% of patients who were ‘rather’ or ‘completely satisfied’ had ‘good’, ‘very good’, or ‘excellent’ QoL.
QoL according to PSD
| n (%) | |||
|---|---|---|---|
| Rather' or ‘completely’ satisfied(n = 200) | Neither satisfied nor dissatisfied(n = 46) | ‘Rather’ or ‘completely’ dissatisfied(n = 18) | |
| Overall QoL | |||
| Very poor, poor, or slightly poor | 28 (14) | 12 (26) | 5 (28) |
| Neither poor nor good | 32 (16) | 12 (26) | 6 (33) |
| Good, very good, or excellent | 140 (70) | 22 (48) | 7 (39) |
Conclusions
In a real world setting, CS symptom control with LAN treatment translates into favourable levels of satisfaction among NET patients. Higher satisfaction levels were consistent with higher global health QoL scores. Further analyses are ongoing to evaluate factors associated with better QoL.
Disclosure
P. Ruszniewski: Ipsen: Consultant/advisory role; honoraria; research funding; partner is Ipsen employee. Novartis: honoraria and research funding; M. Caplin: IPSEN: honoraria for consultant/advisory role. NOVARTIS: Consulting fee, Advisory Committees or Review Panels; LEXICON: Consulting fee, Advisory Committees or Review Panel; J.W. Valle: Ipsen: consulting, honoraria; P. Niccoli: Ipsen: consulting and honoraria; P. Maisonobe: Ipsen: Employment and salary; P. Atlan: Ipsen: Employment and salary. All other authors have declared no conflicts of interest.
Plný text abstraktu v časopise Ann Oncol (2014) 25 (suppl 4)
Datum přednesení příspěvku: 29. 9. 2014
